NCT07386327 Impact of Bupivacaine Dilution With Dextrose or Saline on Infraclavicular Block Outcomes
| NCT ID | NCT07386327 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Burçin Alaçam, MD |
| Condition | Infraclavicular Brachial Plexus Block |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-03-09 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-03-09 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
D5W) has long been used as an intravenous fluid for hydration and energy supplementation and has recently gained increasing clinical interest in perineural injection therapies and ultrasound-guided hydrodissection. D5W has been shown to improve pain and functional outcomes in entrapment neuropathies by mechanically releasing perineural adhesions and potentially modulating neurogenic inflammation. In contrast, 0.9% sodium chloride (normal saline) is routinely used as a dilution medium for local anesthetics in peripheral nerve blocks; however, emerging evidence suggests that alternative diluents such as D5W may influence block onset and efficacy. The infraclavicular block is a commonly used ultrasound-guided technique for brachial plexus anesthesia, providing reliable anesthesia and postoperative analgesia for upper extremity surgery. This study aims to compare the effects of diluting bupivacaine with either D5W or 0.9% NaCl on block success and duration of analgesia in patients undergoing infraclavicular block. Secondary outcomes include block onset characteristics, sensory and motor block profiles, and perioperative analgesic requirements. The findings may help determine whether D5W represents a safe and effective alternative diluent to saline in routine regional anesthesia practice.
Eligibility Criteria
Inclusion Criteria: * Patients who agree to participate in the study and provide written informed consent * Patients scheduled for elective upper extremity surgery for whom infraclavicular block is considered appropriate for anesthetic management * Age between 18 and 65 years * American Society of Anesthesiologists (ASA) physical status I-III * Patients with a normal neurological examination in the extremity scheduled for peripheral nerve block Exclusion Criteria: * Patients who decline to participate in the study or refuse to provide informed consent * History of allergy or hypersensitivity to study medications * Body mass index (BMI) ≥ 30 kg/m² * Body weight less than 40 kg * Age below 18 years or above 65 years * History of significant cardiac disease (e.g., arrhythmia, conduction disorders) * Presence of coagulopathy (international normalized ratio \[INR\] \> 1.5 and/or platelet count \< 100,000/mm³) * Hepatic failure or significant liver dysfunction * Pregnant patients * Infection at the planned peripheral block site * Presence of neurological deficit in the extremity planned for peripheral nerve block * Patients with uncontrolled diabetes mellitus and/or established diabetic neuropathy * American Society of Anesthesiologists (ASA) physical status IV
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07386327 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Infraclavicular Brachial Plexus Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07386327 currently recruiting?
Yes, NCT07386327 is actively recruiting participants. Contact the research team at burcin.ersoy90@gmail.com for enrollment information.
Where is the NCT07386327 trial being conducted?
This trial is being conducted at Sakarya, Turkey (Türkiye).
Who is sponsoring the NCT07386327 clinical trial?
NCT07386327 is sponsored by Burçin Alaçam, MD. The trial plans to enroll 90 participants.